Haemonetics (NYSE: HAE) reported Q2 EPS of $1.27, $0.16 better than the analyst estimate of $1.11. Revenue for the quarter came in at $327 million versus the consensus estimate of $311.46 million.

GUIDANCE:

Haemonetics sees FY2026 EPS of $4.80-$5.00, versus the consensus of $4.83.

For earnings history and earnings-related data on Haemonetics (HAE) click here.